Media coverage about ImmunoGen (NASDAQ:IMGN) has trended somewhat positive on Thursday, according to Accern. The research firm ranks the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ImmunoGen earned a news sentiment score of 0.06 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 45.7612625324152 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the news articles that may have effected Accern’s scoring:
- Radar for In Play Stock – ImmunoGen Inc (NASDAQ: IMGN) (stockspen.com)
- Stock’s Risk Factors to Track – ImmunoGen (NASDAQ:IMGN) (thestockgem.com)
- Is Market views Favorable For financing?: ImmunoGen, Inc., (NASDAQ: IMGN), XL Group Ltd, (NYSE: XL); (tradingnewsnow.com)
- Trading summary of Unusual Activity – ImmunoGen, Inc. (IMGN) (wallstreetmorning.com)
- Librating Stock: ImmunoGen, Inc. (NASDAQ:IMGN) (thestreetpoint.com)
A number of research analysts have recently weighed in on the stock. Leerink Swann reissued an “outperform” rating on shares of ImmunoGen in a research report on Monday. ValuEngine downgraded shares of ImmunoGen from a “hold” rating to a “sell” rating in a research report on Wednesday. Cantor Fitzgerald set a $5.00 target price on shares of ImmunoGen and gave the company a “hold” rating in a research report on Sunday. HC Wainwright set a $18.00 target price on shares of ImmunoGen and gave the company a “buy” rating in a research report on Monday. Finally, Royal Bank of Canada increased their target price on shares of ImmunoGen to $16.00 and gave the company an “outperform” rating in a research report on Wednesday, March 21st. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. ImmunoGen currently has an average rating of “Buy” and a consensus target price of $10.79.
ImmunoGen (NASDAQ:IMGN) last released its quarterly earnings data on Friday, February 9th. The biotechnology company reported ($0.10) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.07) by ($0.03). The company had revenue of $39.40 million for the quarter, compared to the consensus estimate of $39.62 million. The company’s revenue for the quarter was up 185.5% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.39) earnings per share. research analysts forecast that ImmunoGen will post -1.09 earnings per share for the current fiscal year.
In other ImmunoGen news, Director Daniel M. Junius sold 46,667 shares of the stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $10.01, for a total value of $467,136.67. Following the sale, the director now directly owns 243,367 shares in the company, valued at approximately $2,436,103.67. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Richard J. Gregory sold 34,486 shares of the stock in a transaction that occurred on Wednesday, February 21st. The stock was sold at an average price of $10.88, for a total transaction of $375,207.68. Following the completion of the sale, the vice president now owns 239,094 shares in the company, valued at $2,601,342.72. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 232,834 shares of company stock valued at $2,534,433. 6.51% of the stock is owned by insiders.
COPYRIGHT VIOLATION WARNING: This article was posted by BBNS and is owned by of BBNS. If you are viewing this article on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The correct version of this article can be read at https://baseballnewssource.com/2018/03/29/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-immunogen-imgn-stock-price/1971598.html.
ImmunoGen Company Profile
ImmunoGen, Inc is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target.
Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with MarketBeat.com's FREE daily email newsletter.